It looks like your browser is outdated. For the best experience, please consider updating to the latest version or switching to another browser (Firefox, Chrome, Safari).

Skip Navigation

A commitment to investors

We are committed to working on your behalf to build long-term shareholder value in pursuit of our mission.

Our performance


2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.

View our latest Annual Report
0.75 (1.42%)
Baxter International Inc.
NYSE: BAXApr 24, 2017 - 10:54 AM ET
Stock chart for: BAX.  Currently trading at $53.63 with a 52 week high of $53.54 and a 52 week low of $42.22.
Data provided by Nasdaq. Minimum 15 minutes delayed.
See stock & dividend information
Financial Information

Access financial schedules and filings

Shareholder Information

Read the latest FAQs

Spin-Off Information

Find more on the recent spin-off

Investor Conference

View event details and registration

Investor relations contact

Analysts, portfolio managers, and current and prospective shareholders seeking additional investor information can contact Clare Trachtman at +1 (224) 948-3085.

Retail shareholder inquires may directed to Baxter Investor Relations at Global_CORP_Investor_Relations@baxter.com.

Sign up for email alerts